GlassScriptPhysician profile
Orin Zwick
NPI 1467406900
$1,673.59
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $207 · 2021: $84.90 · 2022: $278 · 2023: $816 · 2024: $76.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $892.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $436.87 | 2019-2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $223.92 | 2022-2023 | Cequa |
| Allergan, INC. | $212.71 | 2019-2022 | |
| Biotissue Holdings INC. | $210.29 | 2023 | |
| Oyster Point Pharma, INC. | $117.70 | 2022-2024 | Tyrvaya |
| Abbvie INC. | $91.95 | 2023 | Durysta, Botox |
| Novartis Pharmaceuticals Corporation | $65.99 | 2019-2023 | |
| Alcon Vision LLC | $62.40 | 2022-2023 | Clareon |
| Merz Pharmaceuticals, LLC | $46.26 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $35.94 | 2024 | Xdemvy |
| Thea Pharma INC. | $23.55 | 2023 | Iyuzeh |
| Amgen INC. | $20.09 | 2024 | Tepezza |
| Ocular Therapeutix, INC. | $19.81 | 2019 | |
| Omeros Corporation | $19.02 | 2020 | |
| Dompe US, INC. | $18.70 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $14.69 | 2019 | |
| Aerie Pharmaceuticals, INC. | $14.37 | 2021 | |
| Shire North American Group INC | $14.31 | 2019 | |
| Eyevance Pharmaceuticals LLC | $12.77 | 2022 | |
| Quidel Corporation | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Orin Zwick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.